Literature DB >> 26306399

Cardiovascular disease in Europe--epidemiological update 2015.

Nick Townsend1, Melanie Nichols2, Peter Scarborough3, Mike Rayner3.   

Abstract

This article provides an update for 2015 on the burden of cardiovascular disease (CVD), with a particular focus on coronary heart disease (CHD) and stroke, across the countries of Europe. Cardiovascular disease is still the most common cause of death within Europe, causing almost two times as many deaths as cancer across the continent. Although there is clear evidence, where data are available, that mortality from CHD and stroke has decreased substantially over the last 5-10 years, there are still large inequalities found between European countries, in both current rates of death and the rate at which these decreases have occurred. Similarly, rates of treatment, particularly surgical intervention, differ widely between those countries for which data are available, indicating a range of inequalities between them. This is also the first time in the series that we use the 2013 European Standard Population (ESP) to calculate age-standardized death rates (ASDRs). This new standard results in ASDRs around two times as large as the 1976 ESP for CVD conditions such as CHD but changes little the relative rankings of countries according to ASDR. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiovascular disease; Coronary heart disease; Epidemiology; Morbidity; Mortality; Treatment

Mesh:

Year:  2015        PMID: 26306399     DOI: 10.1093/eurheartj/ehv428

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  124 in total

1.  Oxidized LDL phagocytosis during foam cell formation in atherosclerotic plaques relies on a PLD2-CD36 functional interdependence.

Authors:  Ramya Ganesan; Karen M Henkels; Lucile E Wrenshall; Yasunori Kanaho; Gilbert Di Paolo; Michael A Frohman; Julian Gomez-Cambronero
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

2.  Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population.

Authors:  Nadia Arshad; Trond Isaksen; John-Bjarne Hansen; Sigrid K Brækkan
Journal:  Eur J Epidemiol       Date:  2017-03-17       Impact factor: 8.082

Review 3.  Role of circulating factors in cardiac aging.

Authors:  Antonio Cannatà; Gabriella Marcon; Giovanni Cimmino; Luca Camparini; Giulio Ciucci; Gianfranco Sinagra; Francesco S Loffredo
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 4.  Angiogenic gene therapy in cardiovascular diseases: dream or vision?

Authors:  Seppo Ylä-Herttuala; Charles Bridges; Michael G Katz; Petra Korpisalo
Journal:  Eur Heart J       Date:  2017-05-07       Impact factor: 29.983

5.  Infections in patients using ventricular-assist devices: Comparison of the diagnostic performance of 18F-FDG PET/CT scan and leucocyte-labeled scintigraphy.

Authors:  Carole de Vaugelade; Charles Mesguich; Karine Nubret; Fabrice Camou; Carine Greib; Gael Dournes; Frédéric Debordeaux; Elif Hindie; Laurent Barandon; Ghoufrane Tlili
Journal:  J Nucl Cardiol       Date:  2018-06-12       Impact factor: 5.952

6.  Prevention is better than cure: the new ESC Guidelines.

Authors:  Thomas F Lüscher
Journal:  Eur Heart J       Date:  2016-08-01       Impact factor: 29.983

7.  A novel ultrasonic method for evaluation of blood clotting parameters.

Authors:  Vacis Tatarunas; Algirdas Voleisis; Reimondas Sliteris; Rymantas Kazys; Liudas Mazeika; Vaiva Lesauskaite
Journal:  J Med Ultrason (2001)       Date:  2018-03-13       Impact factor: 1.314

Review 8.  [ECS guidelines 2016 - dyslipidaemias].

Authors:  D Sinning; U Landmesser
Journal:  Herz       Date:  2016-12       Impact factor: 1.443

Review 9.  A practical approach to the pharmacological management of hypertension in older people.

Authors:  Nikesh Parekh; Amy Page; Khalid Ali; Kevin Davies; Chakravarthi Rajkumar
Journal:  Ther Adv Drug Saf       Date:  2016-12-27

10.  Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study - preliminary results.

Authors:  Karolina Obońska; Michał Kasprzak; Kamila Tymosiak; Tomasz Fabiszak; Magdalena Krintus; Jacek Kubica
Journal:  Cardiol J       Date:  2020-11-17       Impact factor: 2.737

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.